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Bronchiolitis is an acute inflammatory injury of the bronchioles that is usually caused by a viral infection in a child <2 years of age. This is one of the most common 
and serious lower respiratory tract infections in infants causing 
breathlessness, cough, and wheezing [1]. It is the major cause of 
morbidity in this age group and leading cause of hospitalization 
with annual hospitalization rates of 17 per 1000 children under 
6 months of age and 3 per 1000 under 2 years of age, mostly in 
children without coexisting illnesses [2]. The most common cause 
(>50%) is respiratory syncytial virus [3], in addition to influenza 
virus, parainfluenza virus, adenovirus, corona viruses, human 
metapneumovirus, and mycoplasma pneumonia [4]. Clinical 
score is generally considered a relative objective instrument to 
assess the severity of bronchiolitis. There are two clinical severity 
scoring systems, more commonly used in viral bronchiolitis. One 
is a respiratory distress assessment instrument which provides a 
score ranging from 0 to 17, with a higher score indicating more 
severe respiratory distress. The other scoring system described by 
Wang et al. provides a score ranging from 0 to 12. A clinical score 
of <4 is considered as mild, score between 4 and 8 as moderate 
and score >9 as severe disease [5].
Despite the high prevalence and morbidity of bronchiolitis 
therapy remains controversial and without widely accepted 
therapeutic guidelines and pharmacotherapy [6]. The current 
treatment of acute bronchiolitis is supportive care in the form 
of supplemental oxygen, fluid therapy, and hypertonic saline 
nebulization [7]. Traditionally, oxygen is provided at 100% 
concentration via low flow nasal prongs as a dry gas which is not 
heated or humidified. However, the latest studies have revealed 
that heated, humidified oxygen therapy high flow nasal cannula 
(HFNC) allows the delivery of high inspired gas flows (up to 
12 L/min in infants) of an air/oxygen mixture which is better than 
the traditional one [8]. The inspired oxygen concentration (FiO2) 
can be varied from 21% to 100% [9]; therefore, giving the greater 
ability to titrate the concentration of oxygen delivered.
HFNC therapy has been used primarily in preterm infants with 
apnea of prematurity and respiratory distress syndrome [10,11]. It is 
possible that HFNC may have similar benefits in older infants with 
bronchiolitis as has been used in children with bronchiolitis [12]. 
Working on the similar hypothesis, we conceived our study to assess 
the efficacy of HFNC oxygen therapy compared with conventional 
low flow nasal cannula oxygen therapy in acute bronchiolitis.
ABSTRACT
Background: Bronchiolitis is a major cause of morbidity and leading cause of hospitalization, mostly in early childhood without 
coexisting illnesses. Traditionally dry oxygen is provided at 100% concentration via low flow nasal prongs. However, the latest 
studies have revealed that oxygen therapy via heated, humidified, high flow nasal cannula (HFNC) allows the delivery of high 
inspired gas flows which is better than the traditional one. Methods: All previously healthy children between 1 and 24 months 
of age with an established clinical diagnosis of moderate to severe bronchiolitis (clinical severity score ≥4) were enrolled for 
study. The patients were divided into two groups: Patients in Group 1 received HFNC oxygen therapy (HFNC group) while 
those in Group 2 received conventional oxygen therapy (non-HFNC group). The patients were randomized in each arm by simple 
randomization. Outcome parameters measured were duration of hospital stay, duration of pediatric intensive care unit (PICU) stay, 
oxygen saturation (SPO2), respiratory rate, adverse event (respiratory failure), need for intermittent positive pressure ventilation or 
continuous positive airway pressure. Results: Out of 100 patients studied, 50 received HFNC oxygen and 50 received conventional 
oxygen. There was early and better improvement in SPO2 and respiratory rate (p<0.001), decreased length of hospital stay (p<0.001) 
and PICU stay (p<0.01) among the patients in HFNC group as compared to non-HFNC group. The most common adverse event 
during the hospital course was respiratory failure which was seen among 4 patients in non-HFNC group and none among HFNC 
group developed such complication. Conclusion: The use of HFNC oxygen therapy in infants hospitalized with acute bronchiolitis 
reduces PICU and hospital stay as well as the potential complications which will substantially reduce the hospital cost.
Key words: Bronchiolitis, High flow oxygen, Hospital stay, Infants
Vol 4 | Issue 2 | Apr - Jun 2017 Indian J Child Health 134
Ahmed et al. High flow nasal cannula oxygen therapy
METHODS
The study was conducted in the postgraduate Department of 
Pediatrics and Neonatology of a Government Medical College, 
Srinagar. It was a comparative study, conducted from April 2014 
to October 2015. The study was duly approved by the ethical 
committee of the institute. All previously healthy children between 
1 and 24 months of age with an established clinical diagnosis of 
moderate to severe bronchiolitis (clinical severity score ≥4, Wang 
et al.) were included in the study. All those with pre-existing 
cardiac disorder, previous wheezing history, pneumonia, upper 
airway abnormality such as choanal atresia, tracheoesophageal 
fistula and cleft palate, and history of foreign body were 
excluded. The patients were randomized into two groups by 
simple randomization to receive either conventional (non-HFNC 
group) or HFNC oxygen therapy (HFNC group). Outcome 
parameters measured were total duration of hospital stay, duration 
of stay in pediatric intensive care unit (PICU), oxygen saturation 
(SpO2), respiratory rate, adverse events (respiratory failure), and 
need for intermittent positive pressure ventilation or continuous 
positive airway pressure. SpO2 and respiratory rate was recorded 
at different time intervals, i.e., at the time of admission and then 
4 h, 8 h, 12 h, and 24 h of admission.
Procedure was explained and an informed consent was 
taken from the parent/guardian before enrolling them in the 
study. Patients were examined at the time of enrollment and 
thereafter. Relevant demographic and clinical data was obtained 
which included the following parameters: Age, sex, duration of 
symptoms, and history of previous wheezing, cardiac disease, and 
foreign body aspiration. Vital parameters (heart rate, respiratory 
rate, and oxygen saturation [SpO2]) were measured and recorded 
at regular intervals. Patients were examined for the presence of 
cyanosis, pallor, and chest retractions. In systemic examination, 
emphasis was laid on breath sounds and presence of rhonchi or 
rhonchi with crepitations. A complete blood count, arterial blood 
gas, and chest X-ray were done in all patients. A clinical score 
was assigned using clinical severity score described by Wang 
et al. [5].
Statistical analysis was done using SPSS version 20.0. Data 
were entered in Microsoft Excel. Continuous variables were 
presented as mean±standard deviation. Categorical variables were 
presented as absolute numbers and percentages. Unpaired t-test, 
and repeated measures ANOVA were used to test the variation 
of continuous variable through time and χ2 test was used to test 
the difference between the two groups. p<0.05 was considered 
statistically significant.
RESULTS
Out of 100 patients studied, 50 received HFNC oxygen and 
50 received conventional oxygen. Out of 100 patients, 68 were 
males and 32 were females with M: F ratio of 2.3:1 among 
HFNC and 1.9:1 among non-HFNC group (p=0.668). The mean 
age among HFNC and non-HFNC group was 5.54±2.11 months 
and 5.69±1.59 months, respectively (p=0.562). There was early 
and better improvement in SpO2 and respiratory rate among the 
patients in HFNC group as compared to non-HFNC group as 
described in Tables 1 and 2. The mean PICU stay among HFNC 
and non-HFNC group was 1.41±0.45 and 3.11±0.76 days, 
respectively (p<0.01). The mean hospital stay among HFNC 
and non-HFNC group was 3.94±0.99 and 6.92±1.34 days, 
respectively (p<0.001). The most common adverse event was 
respiratory failure which was seen in 4 patients in non-HFNC 
group while none of child from HFNC group developed such 
complication. All the 4 patients from non-HFNC group required 
mechanical ventilation (p<0.04).
Table 1: SpO2 level at various points of time intervals of the study 
population
Group n Mean 
SpO2
SD Standard 
error 
mean
p value 
(unpaired 
t-test)
SpO2 0
HFNC 50 82.20 1.161 0.164 0.004
Non-HFNC 50 81.52 1.165 0.165
SpO2 4
HFNC 50 85.28 0.991 0.140 <0.001
Non-HFNC 50 83.12 1.062 0.150
SpO2 8
HFNC 50 87.60 0.881 0.125 <0.001
Non-HFNC 50 84.46 1.249 0.177
SpO2 12
HFNC 50 91.38 0.780 0.110 <0.001
Non-HFNC 50 86.90 1.359 0.192
SpO2 24
HFNC 50 95.90 1.581 0.224 <0.001
Non-HFNC 50 89.88 1.272 0.180
HFNC: High flow nasal cannula, SD: Standard deviation, SEM: Standard error 
mean, SPO2: Oxygen saturation
Table 2: Respiratory rate at various points of time intervals of the 
study population
Group n Mean±SD Standard 
error mean
p value
Respiratory rate 0
HFNC 50 73.46±2.501 0.354 0.506
Non-HFNC 50 73.14±2.286 0.323
Respiratory rate 4
HFNC 50 66.54±3.170 0.448 <0.001
Non-HFNC 50 71.10±2.476 0.350
Respiratory rate 8
HFNC 50 59.66±2.967 0.420 <0.001
Non-HFNC 50 68.64±2.546 0.360
Respiratory rate 12
HFNC 50 49.20±3.387 0.479 <0.001
Non-HFNC 50 61.74±2.954 0.418
Respiratory rate 24
HFNC 50 33.08±2.481 0.351 <0.001
Non-HFNC 50 58.64±2.678 0.379
HFNC: High flow nasal cannula, SD: Standard deviation, SEM: Standard error mean
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DISCUSSION
A total of 100 patients with moderate to severe bronchiolitis 
were included in this study. The mean age at presentation in 
our study was 5.75 months in both groups which is similar to 
earlier reports [13]. The mean respiratory rate (breaths/min) at 
presentation was 73.16 in HFNC and 73.14 in non-HFNC (p=0.5). 
The mean SpO2 at presentation between the two groups was 82% 
and 81% (p=0.41). SPO2 improved more in HFNC group than non-
HFNC at various point of time intervals (p<0.01). These results 
are quite similar with the study done by McKiernan et al. [14], 
who observed that infants who were treated with HFNC had a 
decrease in respiratory rate 1 h after initiation of therapy (18±16 
breaths/min) compared with (6±14 breaths/min) those who did not 
receive HFNC therapy (p<0.001). In another study, Bressan et al. 
observed that use of HFNC for oxygen administration in infants 
with moderate to severe bronchiolitis improves SpO2 levels and 
seems to be associated with decrease in respiratory rate [15].
In our study, duration PICU stay as well as hospital stay 
decreased significantly in the HFNC group. However, it is 
contrary to the studies from other areas of the world [16,17]. 
This could be because of the fact that our study did not have very 
sick population and more stress on mother’s milk. None of the 
patients, who received HFNC oxygen therapy, developed adverse 
event in terms of respiratory failure whereas 4 out of 50 patients, 
who received conventional oxygen developed respiratory failure 
and needed mechanical ventilation (p<0.04). This finding is in 
accordance to the results of the earlier studies [14,18]. However, 
it is contrary to the study done by Kelly et al. where noninvasive 
ventilation failure and recourse to mechanical ventilation was 
8% [19]. In our study, 4 (8%) among the non-HFNC group 
developed respiratory failure and needed mechanical ventilation 
to tie over the crises. HFNC was well tolerated by infants and no 
complication of therapy was seen including nasal or facial trauma 
from the application of the therapy which is congruent with the 
findings of Mayfield et al. [20].
CONCLUSION
We found that the patients treated with humidified heated high 
flow oxygen had statistically significant decrease in the length 
of hospital stay, early improvement in the SPO2, and decrease 
in respiratory rate in comparison to the patients treated with 
conventional low flow oxygen. The patients treated with high flow 
oxygen had significant reduction in the adverse events and need 
for mechanical ventilation as compared to non-high flow group.
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